Payment overview · 2025
General Payments
$255.34
5 reported records · 5 companies
Healthcare provider profile · identity verified
Kylee Wilkinson, FNP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner · ROCKY MOUNT, NC · NPI 1306450119
Verified facts
What the public records show
CMS Open Payments records show Kylee Wilkinson, FNP received $255.34 in general payments during 2025 across 5 reported records.
BETA BIONICS, INC. accounted for 67.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 7 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 442 claims for Jardiance by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNJARDY as an associated drug or biological on 33 records involving 33 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Synjardy by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| BETA BIONICS, INC. | Unresolved — no canonical attribution shown | $171.03 | 67.0% | 1 | 2025 |
| CeQur Corporation | Unresolved — no canonical attribution shown | $37.84 | 14.8% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $16.55 | 6.5% | 1 | 2025 |
| Amneal Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $16.06 | 6.3% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $13.86 | 5.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $255.34 | 5 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| iLet Bionic Pancreas Normalized: ilet bionic pancreas |
Device | BETA BIONICS, INC. | $171.03 | 1 | 2025 |
Source payment records
|
|||||
| iLet Insulin Infusion Kit Contact Detach Normalized: ilet insulin infusion kit contact detach |
Device | BETA BIONICS, INC. | $171.03 | 1 | 2025 |
Source payment records
|
|||||
| iLet Insulin Infusion Kit Inset Normalized: ilet insulin infusion kit inset |
Device | BETA BIONICS, INC. | $171.03 | 1 | 2025 |
Source payment records
|
|||||
| CeQur Simplicity Normalized: cequr simplicity |
Device | CeQur Corporation | $37.84 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $16.55 | 1 | 2025 |
Source payment records
|
|||||
| UNITHROID Normalized: unithroid |
Drug | Amneal Pharmaceuticals LLC | $16.06 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $13.86 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 442 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
442 | 112 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | SYNJARDY open payments reported associated product |
CMS Open Payments — General Payments 33 supporting records · 33 recipient NPIs · example record 1222725005 |
Synjardy · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Ozempic | Semaglutide | 750 | 180 |
| Mounjaro | Tirzepatide | 455 | 83 |
| Jardiance | Empagliflozin | 442 | 112 |
| Tresiba Flextouch U-100 | Insulin Degludec | 342 | 121 |
| Omnipod Dash Pods (Gen 4) | Insulin Pump Cart,cont Inf,bt | 296 | 65 |
| Metformin Hcl Er | Metformin Hcl | 246 | 73 |
| Metformin Hcl | Metformin Hcl | 229 | 66 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 223 | 82 |
| Glimepiride | Glimepiride | 184 | 64 |
| Trulicity | Dulaglutide | 161 | 42 |
| Pioglitazone Hcl | Pioglitazone Hcl | 151 | 45 |
| Farxiga | Dapagliflozin Propanediol | 136 | 40 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 122 | 61 |
| Humalog Kwikpen U-100 | Insulin Lispro | 115 | 53 |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 99 | 25 |
| Humalog | Insulin Lispro | 94 | 36 |
| Novolog Flexpen | Insulin Aspart | 91 | 34 |
| Rybelsus | Semaglutide | 86 | 25 |
| Gvoke Hypopen 2-Pack | Glucagon | 75 | 36 |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 75 | 24 |
| Nateglinide | Nateglinide | 72 | 24 |
| Insulin Lispro | Insulin Lispro | 63 | 18 |
| Humulin R U-500 | Insulin Regular, Human | 62 | suppressed |
| Glipizide | Glipizide | 61 | 28 |
| Tradjenta | Linagliptin | 61 | 17 |
| Humalog Mix 75-25 Kwikpen | Insulin Lispro Protamin/Lispro | 53 | 20 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 48 | 24 |
| Novolog | Insulin Aspart | 46 | 20 |
| Gabapentin | Gabapentin | 43 | 15 |
| Alcohol Pads | Alcohol Antiseptic Pads | 40 | suppressed |
| Humulin R U-500 Kwikpen | Insulin Regular, Human | 40 | 14 |
| Tresiba Flextouch U-200 | Insulin Degludec | 39 | 15 |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 34 | suppressed |
| Glipizide Er | Glipizide | 33 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 32 | 15 |
| Januvia | Sitagliptin Phosphate | 25 | suppressed |
| Levothyroxine Sodium | Levothyroxine Sodium | 23 | suppressed |
| Advocate Pen Needles | Pen Needle, Diabetic | 22 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 22 | 11 |
| Pen Needles | Pen Needle, Diabetic | 22 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Insulin Lispro Protamine Mix | Insulin Lispro Protamin/Lispro | 21 | suppressed |
| Losartan Potassium | Losartan Potassium | 21 | suppressed |
| Lisinopril | Lisinopril | 20 | suppressed |
| Synjardy | Empagliflozin/Metformin Hcl | 19 | suppressed |
| Humulin 70/30 Kwikpen | Insulin Nph Hum/Reg Insulin Hm | 18 | suppressed |
| Gvoke Hypopen 1-Pack | Glucagon | 17 | suppressed |
| Unifine Pentips | Pen Needle, Diabetic | 16 | suppressed |
| Omnipod 5 Dexg7g6 Pods (Gen 5) | Insulin Pump Cart,auto,bt,g6/7 | 15 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Fiasp | Insulin Aspart (Niacinamide) | 13 | suppressed |
| Insulin Aspart | Insulin Aspart | 13 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 12 | suppressed |
| Humalog Kwikpen U-200 | Insulin Lispro | 12 | suppressed |
| Insulin Degludec Pen (U-100) | Insulin Degludec | 12 | 11 |
| Levemir Flexpen | Insulin Detemir | 12 | suppressed |
| Ultra-Fine Micro Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $255.34 · 5 records | BETA BIONICS, INC. | CeQur Simplicity, GVOKE HYPOPEN, JARDIANCE, UNITHROID, iLet Bionic Pancreas, iLet Insulin Infusion Kit Contact Detach, iLet Insulin Infusion Kit Inset | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Boehringer Ingelheim Pharmaceuticals, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error